Fig 2. The MicroB-plex Anti-C6/Anti-pepC10 Immunoassay is concordant with the commercially available Immunetics® C6 Lyme ELISA™ and has greater analytic sensitivity.

Anti-C6 levels were measured in the 32 serum samples from the CDC Lyme Serum Panel I. This collection included eight Two-Tier seropositive samples from patients with: i) convalescent Lyme disease or ii) neurologic Lyme disease or Lyme arthritis. In addition, there were 24 sera from Two-Tier seronegative patients who were: iii) healthy controls; iv) patients who had early acute Lyme (undetectable serum antibody); or v) patients who had potentially confounding medical conditions. Responses were measured using the Immunetics® C6 Lyme ELISA™ (orange dots) and the MicroB-plex Anti-C6/Anti-pepC10 Immunoassay (blue dots). Unpaired t-tests comparing the seronegative and seropositive populations were performed for each assay. A) The Immunetics® C6 Lyme ELISA™ produces a quantitative outcome called the Lyme Index Value. Seropositive patients and seronegative subjects from the CDC Lyme Serum Panel I were readily resolved using serum samples diluted 1:21 (p<0.0001). B) The same serum samples were resolved in the MicroB-plex Anti-C6/Anti-pepC10 Immunoassay using samples diluted 1:1000 (p<0.0001). C) Direct comparison of the MicroB-plex Anti-C6/Anti-pepC10 Immunoassay (blue) and the Immunetics® C6 Lyme ELISA™ (orange) using dilutions of serum from a single positive patient (IMD-EL-004). Orange horizonal line indicates the threshold for seropositivity (C₀) in the Immunetics® C6 Lyme ELISA™; blue horizontal line indicates C₀ for the MicroB-plex Anti-C6/Anti-pepC10 Immunoassay. Vertical lines indicate the serum dilutions at which the C₀ was reached for each assay: 1:5,120 for the Immunetics® C6 Lyme ELISA™ and 1:81,920 for the MicroB-plex Anti-C6/Anti-pepC10 Immunoassay.